Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Return on Sales (2016 - 2025)

Guided Therapeutics' Return on Sales history spans 15 years, with the latest figure at 12.37% for Q3 2025.

  • For Q3 2025, Return on Sales rose 4424.0% year-over-year to 12.37%; the TTM value through Sep 2025 reached 14.78%, up 4183.0%, while the annual FY2024 figure was 345.29%, 30968.0% down from the prior year.
  • Return on Sales for Q3 2025 was 12.37% at Guided Therapeutics, down from 6.91% in the prior quarter.
  • Across five years, Return on Sales topped out at 3.95% in Q3 2021 and bottomed at 2442.0% in Q1 2025.
  • The 5-year median for Return on Sales is 57.21% (2024), against an average of 263.47%.
  • The largest annual shift saw Return on Sales surged 33200bps in 2022 before it crashed -237500bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 7.4% in 2021, then crashed by -4412bps to 333.92% in 2022, then skyrocketed by 96bps to 12.06% in 2023, then plummeted by -5305bps to 652.0% in 2024, then surged by 98bps to 12.37% in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Return on Sales are 12.37% (Q3 2025), 6.91% (Q2 2025), and 2442.0% (Q1 2025).